Combination method for treatment of cancer
AssigneeMerck Sharp & Dohme Corp.
InventorsDarren Shafren, Gough Geoffrey Au
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.
Claims42
A method for the treatment of cancer in a subject comprising (i) intratumorally administering to the subject a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of an anti-PD-1 monoclonal antibody to the subject.
A method for the treatment of an ICAM-1 expressing cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of an ICAM-1 expressing cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day, wherein the injection days are on days 1, 3, 5, 8, 22, 43 and 64, and then at further 3-week intervals and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of melanoma in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of melanoma in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day, wherein the injection days are on days 1, 3, 5, 8, 22, 43 and 64, and then at further 3-week intervals and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of melanoma in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient, and (iii) further comprising the step of tumor resection following (i) and (ii).
A method for the treatment of bladder cancer in a human patient comprising (i) intravesicularly administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of breast cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of liver cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of stomach cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
A method for the treatment of non-small cell lung cancer in a human patient comprising (i) intratumorally administering to the human patient a therapeutically effective amount of Coxsackievirus CVA21 up to a total dose of 3×108 TCID50 per injection day and (ii) systemically co-administering a therapeutically effective amount of anti-PD-1 monoclonal antibody Lambrolizumab to the human patient.
Dependencies are inferred from the claim text.